LLY vs. RHHVF: A Head-to-Head Stock Comparison
Here's a clear look at LLY and RHHVF, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | LLY | RHHVF |
|---|---|---|
| Company Name | Eli Lilly and Company | Roche Holding AG |
| Country | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 786.04 billion USD | 313.72 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | OTC Markets OTCQX |
| Listing Date | June 1, 1972 | February 13, 2009 |
| Security Type | Common Stock | Common Stock |
LLY's market capitalization (786.04 billion USD) is substantially larger than RHHVF's (313.72 billion USD), indicating a significant difference in their market valuations.
Historical Performance
This chart compares the performance of LLY and RHHVF by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LLY | RHHVF |
|---|---|---|
| 5-Day Price Return | -3.55% | 3.86% |
| 13-Week Price Return | -18.05% | -- |
| 26-Week Price Return | 16.33% | -- |
| 52-Week Price Return | 6.88% | -- |
| Month-to-Date Return | -16.52% | -1.23% |
| Year-to-Date Return | -18.28% | -1.23% |
| 10-Day Avg. Volume | 3.10M | 0.88M |
| 3-Month Avg. Volume | 3.20M | 0.88M |
| 3-Month Volatility | 40.07% | -- |
| Beta | 0.58 | 1.46 |
RHHVF carries a higher beta at 1.46, indicating it's more sensitive to market moves, while LLY (beta: 0.58) exhibits greater stability.
Profitability
Return on Equity (TTM)
LLY
97.85%
Pharmaceuticals Industry
- Max
- 39.28%
- Q3
- 20.27%
- Median
- 12.92%
- Q1
- 6.34%
- Min
- -14.55%
LLY's Return on Equity of 97.85% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
RHHVF
--
Pharmaceuticals Industry
- Max
- 39.28%
- Q3
- 20.27%
- Median
- 12.92%
- Q1
- 6.34%
- Min
- -14.55%
Return on Equity data for RHHVF is currently unavailable.
Net Profit Margin (TTM)
LLY
31.66%
Pharmaceuticals Industry
- Max
- 41.87%
- Q3
- 22.21%
- Median
- 14.64%
- Q1
- 9.09%
- Min
- -8.35%
A Net Profit Margin of 31.66% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
RHHVF
--
Pharmaceuticals Industry
- Max
- 41.87%
- Q3
- 22.21%
- Median
- 14.64%
- Q1
- 9.09%
- Min
- -8.35%
Net Profit Margin data for RHHVF is currently unavailable.
Operating Profit Margin (TTM)
LLY
40.35%
Pharmaceuticals Industry
- Max
- 42.93%
- Q3
- 25.68%
- Median
- 18.69%
- Q1
- 12.70%
- Min
- -4.35%
An Operating Profit Margin of 40.35% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RHHVF
--
Pharmaceuticals Industry
- Max
- 42.93%
- Q3
- 25.68%
- Median
- 18.69%
- Q1
- 12.70%
- Min
- -4.35%
Operating Profit Margin data for RHHVF is currently unavailable.
Profitability at a Glance
| Symbol | LLY | RHHVF |
|---|---|---|
| Return on Equity (TTM) | 97.85% | -- |
| Return on Assets (TTM) | 19.76% | -- |
| Net Profit Margin (TTM) | 31.66% | -- |
| Operating Profit Margin (TTM) | 40.35% | -- |
| Gross Profit Margin (TTM) | 83.04% | -- |
Financial Strength
Current Ratio (MRQ)
LLY
1.58
Pharmaceuticals Industry
- Max
- 6.79
- Q3
- 3.64
- Median
- 2.17
- Q1
- 1.38
- Min
- 0.80
LLY's Current Ratio of 1.58 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
RHHVF
--
Pharmaceuticals Industry
- Max
- 6.79
- Q3
- 3.64
- Median
- 2.17
- Q1
- 1.38
- Min
- 0.80
Current Ratio data for RHHVF is currently unavailable.
Debt-to-Equity Ratio (MRQ)
LLY
1.60
Pharmaceuticals Industry
- Max
- 1.60
- Q3
- 0.76
- Median
- 0.28
- Q1
- 0.03
- Min
- 0.00
LLY's leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.60. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
RHHVF
--
Pharmaceuticals Industry
- Max
- 1.60
- Q3
- 0.76
- Median
- 0.28
- Q1
- 0.03
- Min
- 0.00
Debt-to-Equity Ratio data for RHHVF is currently unavailable.
Interest Coverage Ratio (TTM)
LLY
41.08
Pharmaceuticals Industry
- Max
- 154.61
- Q3
- 67.33
- Median
- 13.25
- Q1
- 2.96
- Min
- -27.02
LLY's Interest Coverage Ratio of 41.08 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
RHHVF
--
Pharmaceuticals Industry
- Max
- 154.61
- Q3
- 67.33
- Median
- 13.25
- Q1
- 2.96
- Min
- -27.02
Interest Coverage Ratio data for RHHVF is currently unavailable.
Financial Strength at a Glance
| Symbol | LLY | RHHVF |
|---|---|---|
| Current Ratio (MRQ) | 1.58 | -- |
| Quick Ratio (MRQ) | 0.78 | -- |
| Debt-to-Equity Ratio (MRQ) | 1.60 | -- |
| Interest Coverage Ratio (TTM) | 41.08 | -- |
Growth
Revenue Growth
Revenue Growth at a Glance
| Symbol | LLY | RHHVF |
|---|---|---|
| Revenue Growth (MRQ vs Prior YoY) | 42.56% | -- |
| Revenue Growth (TTM vs Prior YoY) | 44.70% | -- |
| 3-Year Revenue CAGR | 31.69% | -- |
| 5-Year Revenue CAGR | 21.58% | -- |
EPS Growth
EPS Growth at a Glance
| Symbol | LLY | RHHVF |
|---|---|---|
| EPS Growth (MRQ vs Prior YoY) | 51.33% | -- |
| EPS Growth (TTM vs Prior YoY) | 95.89% | -- |
| 3-Year EPS CAGR | 49.25% | -- |
| 5-Year EPS CAGR | 27.59% | -- |
Dividend
Dividend Yield (TTM)
LLY
0.65%
Pharmaceuticals Industry
- Max
- 6.35%
- Q3
- 3.00%
- Median
- 1.84%
- Q1
- 0.00%
- Min
- 0.00%
LLY's Dividend Yield of 0.65% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
RHHVF
0.00%
Pharmaceuticals Industry
- Max
- 6.35%
- Q3
- 3.00%
- Median
- 1.84%
- Q1
- 0.00%
- Min
- 0.00%
RHHVF currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
LLY
26.09%
Pharmaceuticals Industry
- Max
- 188.03%
- Q3
- 80.63%
- Median
- 44.08%
- Q1
- 0.00%
- Min
- 0.00%
LLY's Dividend Payout Ratio of 26.09% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
RHHVF
0.00%
Pharmaceuticals Industry
- Max
- 188.03%
- Q3
- 80.63%
- Median
- 44.08%
- Q1
- 0.00%
- Min
- 0.00%
RHHVF has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | LLY | RHHVF |
|---|---|---|
| Dividend Yield (TTM) | 0.65% | 0.00% |
| Dividend Payout Ratio (TTM) | 26.09% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
LLY
40.21
Pharmaceuticals Industry
- Max
- 40.21
- Q3
- 26.28
- Median
- 18.77
- Q1
- 14.14
- Min
- 3.46
A P/E Ratio of 40.21 places LLY in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company's future growth.
RHHVF
--
Pharmaceuticals Industry
- Max
- 40.21
- Q3
- 26.28
- Median
- 18.77
- Q1
- 14.14
- Min
- 3.46
P/E Ratio data for RHHVF is currently unavailable.
Price-to-Sales Ratio (TTM)
LLY
12.73
Pharmaceuticals Industry
- Max
- 7.19
- Q3
- 4.85
- Median
- 2.51
- Q1
- 1.94
- Min
- 0.83
With a P/S Ratio of 12.73, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
RHHVF
--
Pharmaceuticals Industry
- Max
- 7.19
- Q3
- 4.85
- Median
- 2.51
- Q1
- 1.94
- Min
- 0.83
P/S Ratio data for RHHVF is currently unavailable.
Price-to-Book Ratio (MRQ)
LLY
38.29
Pharmaceuticals Industry
- Max
- 10.12
- Q3
- 5.02
- Median
- 2.39
- Q1
- 1.54
- Min
- 0.63
At 38.29, LLY's P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market's valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
RHHVF
--
Pharmaceuticals Industry
- Max
- 10.12
- Q3
- 5.02
- Median
- 2.39
- Q1
- 1.54
- Min
- 0.63
P/B Ratio data for RHHVF is currently unavailable.
Valuation at a Glance
| Symbol | LLY | RHHVF |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 40.21 | -- |
| Price-to-Sales Ratio (TTM) | 12.73 | -- |
| Price-to-Book Ratio (MRQ) | 38.29 | -- |
| Price-to-Free Cash Flow Ratio (TTM) | 109.69 | -- |